Sage Therapeutics depression drug disappoints

Sage Therapeutics took an 18.8 percent dive to USD 59.15 in the US pre-market after the US biotech firm generated disappointing results from a trial involving a potential treatment for severe depression.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Fate of Biogen’s stock rides on Alzheimer’s drug decision
For subscribers